Therapeutic goods administration has approved the miracle drug-Herceptin after declaring it safe and effective for the treatment of early stage HER-2 Breast cancer. The approval binds Roche, the drug manufacturer to ensure that sufficient warnings are available on the packaging along with timely updates regarding its performance.
The drug is on its last lap of government approval after which subsidy to use this drug will not be a distant dream. The drug is estimated at an annual cost of $66,000.The respite for patients to use Herceptin is now very much on the cards, after sufferers have been literally beseeching the government for some form of subsidy, as few are able to actually afford it, despite the approval accorded to prescribe the drug.
Show Full Article